Fresenius SE EPS - Earnings per Share 2016-2024 | FSNUY
Fresenius SE annual and quarterly earnings per share history from 2016 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Fresenius SE EPS for the quarter ending September 30, 2024 was $0.16, a 181.12% decline year-over-year.
- Fresenius SE EPS for the twelve months ending September 30, 2024 was $-0.18, a 250% decline year-over-year.
- Fresenius SE 2023 annual EPS was $-0.28, a 144.17% decline from 2022.
- Fresenius SE 2022 annual EPS was $0.64, a 33.3% decline from 2021.
- Fresenius SE 2021 annual EPS was $0.96, a 10.3% increase from 2020.
| Fresenius SE Annual EPS |
| 2023 |
$-0.28 |
| 2022 |
$0.64 |
| 2021 |
$0.96 |
| 2020 |
$0.87 |
| 2019 |
$0.95 |
| 2018 |
$1.07 |
| 2017 |
$0.92 |
| 2016 |
$0.80 |
| 2015 |
$0.69 |
| Fresenius SE Quarterly EPS |
| 2024-09-30 |
$0.16 |
| 2024-06-30 |
$-0.18 |
| 2024-03-31 |
$0.13 |
| 2023-12-31 |
$-0.29 |
| 2023-09-30 |
$-0.20 |
| 2023-06-30 |
$0.04 |
| 2023-03-31 |
$0.16 |
| 2022-12-31 |
$0.11 |
| 2022-09-30 |
$0.14 |
| 2022-06-30 |
$0.18 |
| 2022-03-31 |
$0.21 |
| 2021-12-31 |
$0.26 |
| 2021-09-30 |
$0.22 |
| 2021-06-30 |
$0.25 |
| 2021-03-31 |
$0.24 |
| 2020-12-31 |
$0.22 |
| 2020-09-30 |
$0.23 |
| 2020-06-30 |
$0.20 |
| 2020-03-31 |
$0.23 |
| 2019-12-31 |
$0.26 |
| 2019-09-30 |
$0.22 |
| 2019-06-30 |
$0.24 |
| 2019-03-31 |
$0.23 |
| 2018-12-31 |
$0.26 |
| 2018-09-30 |
$0.22 |
| 2018-06-30 |
$0.35 |
| 2018-03-31 |
$0.24 |
| 2017-12-31 |
$0.27 |
| 2017-09-30 |
$0.21 |
| 2017-06-30 |
$0.22 |
| 2017-03-31 |
$0.22 |
| 2016-12-31 |
$0.22 |
| 2016-09-30 |
$0.20 |
| 2016-06-30 |
$0.20 |
| 2016-03-31 |
$0.18 |
| 2015-12-31 |
$0.18 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$21.703B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
